Authors: Francesc Xavier AvilésJurado Ximena Terra David Gómez Joan Carles Flores Antoni Raventós Elsa MaymóMasip Xavier León Vicente SerranoGonzalvo Joan Vendrell Enric Figuerola Matilde R Chacón
Publish Date: 2014/05/26
Volume: 272, Issue: 7, Pages: 1733-1741
Abstract
Identifying serum pretreatment molecular markers that can predict response to therapy is of great interest in head and neck oncology and is required to develop personalized treatments that maximize survival while minimizing morbidity The main aim was to investigate the potential prognostic significance of tumor necrosis factorlike weak inducer of apoptosis TWEAK and its receptors fibroblast growth factorinducible 14 Fn14 and CD163 in head and neck squamous cell carcinoma HNSCC The study comprised 37 consecutive patients with pathologically confirmed untreated HNSCC Serum and tissue samples from these patients were available for study We determined sTWEAK and sCD163 levels in serum from 37 HNSCC patients by ELISA TWEAK CD163 Fn14 and TNFα gene expression were detected by realtime RTPCR in 111 matched tissue samples tumoral adjacent and distal/normal mucosa Our results showed a significant relationship between low sTWEAK levels and poor locoregional control of the disease Kaplan–Meier curves indicated that the locoregional recurrencefree survival rate in patients with low sTWEAK circulating levels was significantly lower than in patients with high levels and that high CD136/TWEAK expression ratio in tumors was also related to poor prognosis sTWEAK pretreatment serum levels might be used as prognostic noninvasive biomarkers for locoregional control in patients with HNSCC Future investigations are warranted to determine the potential prognostic significance of this noninvasive biomarker in the rapid discrimination according to the locoregional control achieved in patients who received a nonsurgical organ preservation treatmentThis study was supported by the Institut d’Investigació Sanitària Pere Virgili Tarragona Catalonia IISPV and by the Instituto de Salud Carlos III Ministerio de Economia y Competitividad Spain Grant Numbers PI11/00049 to MRCH PI11/00085 to JV and PI11/02380 to XL MRCH is supported by the Research Stabilization Programme of the Instituto de Salud Carlos III ISCIII cofinanced by Institut Català de Salut ICS in Catalonia Spain We express our gratitude to Meritxell Cortés and Jessica Capera for their assistance in sample collection
Keywords: